for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Daewoong Pharmaceutical Co., Ltd.

069620.KS

Latest Trade

118,500.00KRW

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

63,200.00

 - 

182,000.00

As of on the Korea Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
118,500.00
Open
--
Volume
--
3M AVG Volume
8.58
Today's High
--
Today's Low
--
52 Week High
182,000.00
52 Week Low
63,200.00
Shares Out (MIL)
10.76
Market Cap (MIL)
1,355,629.00
Forward P/E
64.24
Dividend (Yield %)
0.51

Next Event

Q3 2020 Daewoong Pharma Earnings Release

Latest Developments

More

Daewoong Pharmaceutical Unveils Phase 3 Clinical Data Of Fexuprazan, A Novel Potassium-Competitive Acid Blocker

Avacta And Daewoong Establish Joint Venture

Daewoong Acquires Shares Worth 5 Billion Won In Daewoong Pharma

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Daewoong Pharmaceutical Co., Ltd.

DAEWOONG PHARMACEUTICAL CO.,LTD. is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals. The Company's products mainly include antihypertensive drugs, antianemic agents, antidiabetic agents, antiemetic agents, antihistamine agents, antimicrobials, antineoplastics, antiobesity agents, antipyretic agents, analgesic agents, anti-inflammatory agents, biosimilars, remedies for bone and joint diseases, cardiovascular treatments, central nervous system treatments, digestive agents, dermatologic agents, gastrointestinal agents, health supplements and respiratory remedies, among others. The Company distributes its products within domestic markets and to overseas markets.

Industry

Biotechnology & Drugs

Contact Info

35-14, Jeyakgongdan 4-gil, Hyangnam-eup

18623

South Korea

+82.2.5508800

http://www.daewoong.com

Executive Leadership

Yeong Hwan Yoon

Chairman of the Board

Jong Wuk Lee

President, Co-Chief Executive Officer, Director

Jae Hun Yoon

Vice Chairman of the Board, Co-Chief Executive Officer

Jae Seung Yoon

Vice Chairman of the Board

Jae Hong Park

Managing Director

Key Stats

2.23 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, KRW)

2017

1.0K

2018

1.0K

2019

1.1K

2020(E)

1.0K
EPS (KRW)

2017

3,060.000

2018

-1,468.000

2019

2,132.000

2020(E)

2,766.138
Price To Earnings (TTM)
71.77
Price To Sales (TTM)
1.22
Price To Book (MRQ)
2.32
Price To Cash Flow (TTM)
21.40
Total Debt To Equity (MRQ)
72.33
LT Debt To Equity (MRQ)
54.30
Return on Investment (TTM)
2.99
Return on Equity (TTM)
1.94

Latest News

Latest News

BRIEF-Evolus Says Daewoong Pharmaceutical to invest $40 Million in Co

* EVOLUS STRENGTHENS BALANCE SHEET; SECURES $40 MILLION INVESTMENT

South Korea's Daewoong Pharmaceutical says anti-parasitic drug effective against coronavirus in animal tests

South Korea's Daewoong Pharmaceutical <069620.KS> said its anti-parasitic drug niclosamide had eliminated the novel coronavirus from animals' lungs during testing.

BRIEF-Daewoong Pharmaceutical Unveils Phase 3 Clinical Data Of Fexuprazan, A Novel Potassium-Competitive Acid Blocker

* DAEWOONG PHARMACEUTICAL UNVEILS PHASE 3 CLINICAL DATA OF FEXUPRAZAN, A NOVEL POTASSIUM-COMPETITIVE ACID BLOCKER

BRIEF-Daewoong Pharma to pay annual cash dividend as 600 won/share

* Says it plans to pay annual cash dividend as 600 won/share to shareholders of record on Dec. 31, 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up